Profile
| Metric | Value |
|---|---|
| Full Name | Arcellx, Inc. |
| Ticker | NASDAQ: ACLX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | arcellx.com |
| Employees | 163 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $68.62 | |
| Price, 1D Change | -0.36% | |
| Market Cap | $4B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.86 | |
| Revenue | $108M | |
| Revenue, 1Y Change | -2.16% | |
| EPS | -$2.00 | |
| EPS, 1Y Change | -36.25% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.00 | |
| EPS Estimate | -$4.01 | |
| EPS Est. Change | -100.03% | |
| Revenue | $107.94M | |
| Revenue Estimate | $32.78M | |
| Revenue Est. Change | -69.63% | |
| Current Price | $68.62 | |
| Price Target | - | $112.00 |
| Price Tgt. Change | - | +63.22% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.51 | -$1.47 | +41.40% | |
| -$1.50 | -$2.00 | -33.32% | |
| -$4.01 | N/A | -100.03% | |
| -$3.39 | N/A | -69.06% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $110.32M | $110.32M | 0.00% | |
| $121.71M | $107.94M | -11.32% | |
| $32.78M | N/A | -69.63% | |
| $118.92M | N/A | +10.18% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +4.94% | |
| Price, 3Y | +107.88% | |
| Market Cap, 1Y | +11.76% | |
| Market Cap, 3Y | +172.53% | |
| Revenue, 1Y | -2.16% | |
| Revenue, 3Y | +100.00% | |
| EPS, 1Y | -36.25% | |
| EPS, 3Y | -10.23% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $68.62 | |
| SMA 200 | $71.28 | |
| SMA 200 vs Price | +3.87% | |
| SMA 50 | $72.27 | |
| SMA 50 vs Price | +5.32% | |
| Beta | 0.86 | |
| ATR | $3.64 | |
| 14-Day RSI | 50.71 | |
| 10-Day Volatility | 50.27% | |
| 1-Year Volatility | 51.59% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $107.94M | |
| EPS | -$2.00 | |
| Gross Profit | $102.75M | |
| Gross Margin | 95.19% | |
| Operating Profit | -$137.57M | |
| Operating Margin | -127.46% | |
| Net Income | -$107.35M | |
| Net Margin | -99.46% | |
| EBITDA | -$99.06M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.12 | |
| Current Ratio | 4.78 | |
| Quick Ratio | 4.78 | |
| - | ||
| F-Score | 2 | |
| Altman Z-Score | 8.77 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 110.53 | |
| PB Ratio | 9.00 | |
| EV/EBITDA | -15.09 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $454.79M | |
| Cash & Equivalents | $105.68M | |
| Total Assets | $711.33M | |
| Current Assets | $599.31M | |
| Total Liabilities | $256.54M | |
| Current Liabilities | $125.41M | |
| Total Debt | $54.08M | |
| Short Term Debt | $7.54M | |
| Accounts Payable | $2.10M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $245.51M | |
| Operating Expenses | $245.51M | |
| Cost Of Goods Sold | $5.19M | |
| SG&A | $88.41M | |
| D&A | $5.19M | |
| Interest Expense | $0.00 | |
| Income Tax | $2.07M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$83.47M | |
| CFI | -$183.05M | |
| CFF | -$24.09M | |
| Capex | $13.43M | |
| Free Cash Flow | -$96.90M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | ||
| Needham | → | |
| Canaccord Genuity | → | |
| Wolfe Research | ||
| Canaccord Genuity | → | |
| Scotiabank | → | |
| Citigroup | ||
| HC Wainwright & Co. | → | |
| Scotiabank | → | |
| UBS | → |
Analyst sentiment
Institutional ownership
Screeners with ACLX
FAQ
What is the ticker symbol for Arcellx, Inc.?
The ticker symbol for Arcellx, Inc. is NASDAQ:ACLX
Does Arcellx, Inc. pay dividends?
No, Arcellx, Inc. does not pay dividends
What sector is Arcellx, Inc. in?
Arcellx, Inc. is in the Healthcare sector
What industry is Arcellx, Inc. in?
Arcellx, Inc. is in the Biotechnology industry
What country is Arcellx, Inc. based in?
Arcellx, Inc. is headquartered in United States
When did Arcellx, Inc. go public?
Arcellx, Inc. initial public offering (IPO) was on February 4, 2022
Is Arcellx, Inc. in the S&P 500?
No, Arcellx, Inc. is not included in the S&P 500 index
Is Arcellx, Inc. in the NASDAQ 100?
No, Arcellx, Inc. is not included in the NASDAQ 100 index
Is Arcellx, Inc. in the Dow Jones?
No, Arcellx, Inc. is not included in the Dow Jones index
When was Arcellx, Inc. last earnings report?
Arcellx, Inc.'s most recent earnings report was on November 5, 2025
When does Arcellx, Inc. report earnings?
The next expected earnings date for Arcellx, Inc. is February 26, 2026
Data Sources & References
- ACLX Official Website www.arcellx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1786205/000119312525266932/0001193125-25-266932-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1786205/000095017025029150/0000950170-25-029150-index.htm
- ACLX Profile on Yahoo Finance finance.yahoo.com/quote/ACLX
- ACLX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/aclx